Status: Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.
Participants needed: 68
Trial details
Phase: Phase 1, Phase 2Age: 25-60Biological sex: AllType: InterventionalSponsor: Vico Therapeutics B. V.Updated: Aug 28, 2025Locations: 14
Eligibility criteria
Provide written informed consent (signed and dated). Patients should be assessed... [+7]
Have any condition that would prevent participation in trial assessments. [+11]